We have long experience of developing cell-based iLite® assays for a wide range of targets. Our ready-to-use assays offer a fast and streamlined work process with low variability. We are now happy to announce that we have expanded our portfolio with a RANKL iLite functional assay. This is exciting as there is much interest in developing new antibody-based drugs against this molecule.
Our RANKL iLite assay is ideal for potency measurements of anti-RANKL candidate drugs and studies of RANKL or RANKL agonists. As an added benefit, the RANKL iLite assay contains a luciferase normalization gene which can be used to compensate for differences in cell number and viability as well as serum matrix effects.